These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15244384)

  • 1. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Schroeder G; Tefferi A
    Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
    Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
    Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
    J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
    Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
    Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
    Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
    Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
    Br J Haematol; 2002 May; 117(2):288-96. PubMed ID: 11972510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M
    Br J Haematol; 2001 Jul; 114(1):78-83. PubMed ID: 11472348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
    Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
    Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
    Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
    Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
    Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
    Berrebi A; Feldberg E; Spivak I; Shvidel L
    Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
    Merup M; Kutti J; Birgergård G; Mauritzson N; Björkholm M; Markevärn B; Maim C; Westin J; Palmblad J;
    Med Oncol; 2002; 19(2):79-86. PubMed ID: 12180484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
    Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
    J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
    J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
    Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
    Faoro LN; Tefferi A; Mesa RA
    Eur J Haematol; 2005 Feb; 74(2):117-20. PubMed ID: 15654901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide in agnogenic and secondary myelofibrosis.
    Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
    Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.